Bellicum Pharmaceuticals Profile

USD 0.11  1.38%

Acquisition by Alan Musso of 7500 shares of Bellicum Pharmaceuticals subject to Rule 16b-3

Bellicum Pharmaceuticals Inc insider trading alert for grant of restricted stock units by Alan Musso, CFO and Treasurer, on March 16, 2018. This event was filed by Bellicum Pharmaceuticals with SEC on 2017-01-05. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Bellicum Pharmaceuticals Summary

Bellicum Pharmaceuticals Inc (BLCM) is traded on NASDAQ General Markets in USA. It is located in TEXAS, U.S.A and employs 110 people. Bellicum Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 268.37 M. Bellicum Pharmaceuticals Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 33.26 M outstanding shares of which 4.4 M shares are currently shorted by private and institutional investors with about 12.16 trading days to cover. Bellicum Pharmace currently holds about 98.9 M in cash with (72.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.97.
Check Bellicum Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected Bellicum Pharmaceuticals Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Bellicum Pharmaceuticals Against Markets

Current Ratings

Bellicum Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
< 21% 
Equity ratings for Bellicum Pharmaceuticals Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas. Bellicum Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets exchange. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameBellicum Pharmaceuticals Inc
President CEO, DirectorRichard FairView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
LocationTEXAS, U.S.A
Business Address2130 West Holcombe Boulevard
ExchangeNASDAQ General Markets
CIK Number01358403.0
Contact Number832 384 1100
CurrencyUSD - US Dollar


Bellicum Pharmaceuticals Analyst Recommendations
Target PriceAdvice# of Analysts
Bellicum Pharmaceuticals Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Bellicum Pharmaceuticals Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


Bellicum Pharmaceuticals Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.67March 13, 2017
Bellicum Pharmaceuticals Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


Bellicum Pharmaceuticals Corporate Directors
Frank McGuyer Director
Stephen Davis Independent Director
Reid Huber Director, Ph.D